Previous 10 | Next 10 |
aTyr Pharma ( NASDAQ: LIFE ) shares fell over 7% premarket on Thursday after the biotherapeutics company priced its public offering of 22,225,000 shares at $2.25 per share. Underwriters have been granted a 30-day option to purchase up to an additional 3,333,750 shares at the p...
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public ...
Summary aTyr Pharma is a biotherapeutics company focusing on tRNA synthetase research. The company's main product candidate is efzofitimod, a potential treatment for fibrotic lung diseases. In an early-stage study, efzofitimod appeared to show statistically nonsignificant positive t...
aTyr Pharma ( NASDAQ: LIFE ) is trading 10.5% lower after the bell after the company announced an underwritten public offering of its common stock. aTyr expects to grant the underwriters a 30-day option to purchase additional shares for an amount up to an additional 15% of th...
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has commenced an underwritten public offering of sha...
aTyr Pharma ( NASDAQ: LIFE ) shares rose ~5% on above-average volume on Monday after announcing that its partner Kyorin has started dosing in the pivotal Phase 3 study for lead asset efzofitimod in sarcoidosis, triggering a milestone payment worth $10M. aTyr ( LIFE ) has inked...
$10M milestone payment triggered by advancement of clinical program in Japan. Multiple centers in the U.S. and Japan are now open for enrollment. SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a biotherapeutics company engaged in...
Symposia presentation to highlight significant advancements in understanding of efzofitimod’s MOA Poster presentation analyzing exposure-efficacy of efzofitimod further supports clinical proof-of-concept SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ...
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Patent Office (EPO) has provided a Notice ...
European Commission (EC) granted orphan drug designation to aTyr Pharma's ( NASDAQ: LIFE ) efzofitimod to treat sarcoidosis. Sarcoidosis is a disorder characterized by the growth of tiny collections of inflammatory cells (granulomas) in any body part, commonly the lungs and lymph ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...